A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases

Table 2 Study Regimen Description

Agent	Dose	Route	Schedule	Cycle Length
Sn-117 m-DTPA	20 mCi/70 kg (0.28 mCi/kg)	IV injection over 5–10 min	Day 1	8 weeks*

*Retreatment after two cycles is allowed if patients meet the following retreatment criteria: Pain (≥ 4 on 11-point intensity scale) recurs within 6 months after a 16-week pain observation period and no disease progression on bone scans (≤ 2 new bone lesions), or evidence of clinical progression (such as development of cancer-related symptoms). The maximum treatment doses per patient is four injections in this study (2 rounds of 2 injection cycles)

ISSN: 1471-2407